BOAN BIOTECH (06955) surged over 14%, and as of press time, the stock was up 10.46% to HK$14.36 with a turnover of HK$290 million.

Huaan Securities noted that BOAN BIOTECH maintained reasonable cost control in the first half of the year. The launch of the new denosumab product led to a temporary decline in gross margin, while R&D expense ratio decreased dynamically in the short term and sales expense ratio fluctuated reasonably. The company currently maintains abundant cash reserves, supporting rapid advancement of its innovative drug pipeline.

Furthermore, leveraging years of experience in the complete value chain from molecular discovery to clinical development and production quality control through its macromolecule platform, BOAN BIOTECH has established four major technology platforms: the fully human antibody transgenic mouse platform, bispecific TCE technology platform, ADC technology platform, and AI application platform, focusing on next-generation IO+ADC therapies.

The company's BA-huMab fully human antibody transgenic mouse platform incorporates 30 human antibody κ light chain variable region genes and 110 human antibody heavy chain variable region genes (IgM and IgG1), enabling rapid immune response induction and generating high antibody titers post-immunization, which has been validated across numerous antibody projects.

On the ADC platform, the company continues platform upgrades from differentiated toxin and indication-focused CLDN18.2 ADC, to differentiated target CD228 ADC, to next-generation dual-antibody ADC, and dual-toxin ADC.

Huaan Securities remains optimistic about the company's comprehensive biopharmaceutical platform capabilities and the significant market potential of its FIC innovative pipeline.